

1 **An integrated analysis of contact tracing and genomics to assess the efficacy of travel
2 restrictions on SARS-CoV-2 introduction and transmission in England from June to
3 September, 2020**

4
5 *Dinesh Aggarwal^{1,2,3,4}, Andrew J. Page^{5,^}, Ulf Schaefer^{2,^}, George M. Savva⁵, Richard
6 Myers², Erik Volz⁶, Nicholas Ellaby², Steven Platt², Natalie Groves², Eileen Gallagher²,
7 Niamh M. Tumelty⁷, Thanh Le Viet⁵, Gareth J. Hughes⁸, Cong Chen², Charlie Turner²,
8 Sophie Logan⁹, Abbie Harrison², The COVID-19 Genomics UK (COG-UK) Consortium^{10,#},
9 Sharon J. Peacock^{1,2,3,4}, Meera Chand^{2^^}, *Ewan M. Harrison^{1,2,4,11^^}

10 **Affiliations**

- 11 1. University of Cambridge, Department of Medicine, Cambridge, UK.
12 2. Public Health England, 61 Colindale Ave, London, NW9 5EQ, UK.
13 3. Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
14 4. Wellcome Sanger Institute, Hinxton, Cambridge, UK.
15 5. Quadram Institute Bioscience, Norwich Research Park, Norwich, NR4 7UQ, UK.
16 6. Imperial College London, Department of Infectious Disease Epidemiology, London, UK.
17• 7. University of Cambridge, Cambridge University Libraries, Cambridge, UK
18• 8. Public Health England National Infections Service, Field Service, Leeds, UK.
19• 9. Public Health England, National Infections Service, Field Service, Nottingham, UK.
20 10. <https://www.cogconsortium.uk>
21 11. University of Cambridge, Department of Public Health and Primary Care, Cambridge,
22 UK.
23

24 # Full list of consortium names and affiliations are in the appendix

25 ^ Contributed equally

26 ^^ Contributed equally (joint senior authors)

27 * corresponding authors:

28 Dr Dinesh Aggarwal, University of Cambridge, Department of Medicine, Cambridge, UK.
29 Email: dinesh.aggarwal@nhs.net

30 Dr Ewan Harrison, Wellcome Sanger Institute, Hinxton, Cambridge, UK. Email:
31 eh6@sanger.ac.uk

54 **Abstract**

55 **Background:** Mitigation of SARS-CoV-2 transmission from international travel is a priority.

56 Travellers from countries with travel restrictions (closed travel-corridors) were required to
57 quarantine for 14 days over Summer 2020 in England. We describe the genomic
58 epidemiology of travel-related cases in England and evaluate the effectiveness of this travel
59 policy.

60 **Methods:** Between 27/05/2020 and 13/09/2020, probable travel-related SARS-CoV-2 cases
61 and their contacts were identified and combined with UK SARS-CoV-2 sequencing data. The
62 epidemiology and demographics of cases was identified, and the number of contacts per
63 case modelled using negative binomial regression to estimate the effect of travel restriction,
64 and any variation by age, sex and calendar date. Unique travel-related SARS-CoV-2
65 genomes in the COG-UK dataset were identified to estimate the effect travel restrictions on
66 cluster size generated from these. The Polecat Clustering Tool was used to identify a travel-
67 related SARS-CoV-2 cluster of infection.

68 **Findings:** 4,207 travel-related SARS-CoV-2 cases are identified. 51.2% (2155/4207) of
69 cases reported travel to one of three countries; 21.0% (882) Greece, 16.3% (685) Croatia
70 and 14.0% (589) Spain. Median number of contacts per case was 3 (IQR 1-5), and greatest
71 for the 16-20 age-group (9.0, 95% C.I.=5.6-14.5), which saw the largest attenuation by travel
72 restriction. Travel restriction was associated with a 40% (rate ratio=0.60, 95% C.I.=0.37-
73 0.95) lower rate of contacts. 827/4207 (19.7%) of cases had high-quality SARS-CoV-2
74 genomes available. Fewer genetically-linked cases were observed for index cases related
75 to countries with travel restrictions compared to cases from non-travel restriction countries
76 (rate ratio=0.17, 95% C.I.=0.05-0.52). A large travel-related cluster dispersed across
77 England is identified through genomics, confirmed with contact-tracing data.

78 **Interpretation:** This study demonstrates the efficacy of travel restriction policy in reducing
79 the onward transmission of imported cases.

80 **Funding:** Wellcome Trust, Biotechnology and Biological Sciences Research Council, UK
81 Research & Innovation, National Institute of Health Research, Wellcome Sanger Institute.

82

83

84

85

86

87

88

89

90

91 RESEARCH IN CONTEXT

92 *Evidence before this study*

93 We searched PubMed, medRxiv, bioRxiv, Web of Science and Scopus for the terms
94 (COVID-19 OR SARS-COV-2) AND (imported or importation) AND (sequenc* OR genom* or
95 WGS). We filtered the 55 articles identified through this search and rejected any that did not
96 undertake SARS-CoV-2 sequencing as part of an epidemiological investigation for
97 importation into a different country. The remaining 20 papers were reviewed in greater detail
98 to understand the patterns of importation and the methods used in each case.

99

100 *Added value of this study*

101 This is the first published study on importations of SARS-CoV-2 into England using
102 genomics. Plessis et al., (2021) used a predictive model to infer the number of importations
103 in to the UK from all SARS-CoV-2 genomes generated before 26th June 2020. The current
104 study assesses the period 27/05/2020 to 13/09/2020 and presents findings of case-reported
105 travel linked to genomic data. Two unpublished reports exist for Wales and Scotland,
106 although only examine a comparatively small number of importations.

107

108 *Implications of all the available evidence*

109 This large-scale study has a number of findings that are pertinent to public health and of
110 global significance, not available from prior evidence to our knowledge. The study
111 demonstrates travel restrictions, through the implementation of 'travel-corridors', are
112 effective in reducing the number of contacts per case based on observational data. Age has
113 a significant effect on the number of contacts and this can be mitigated with travel
114 restrictions. Analysis of divergent clusters indicates travel restrictions can reduce the number
115 of onwards cases following a travel-associated case. Analysis of divergent clusters can allow
116 for importations to be identified from genomics, as subsequently evidenced by cluster
117 characteristics derived from contact tracing. The majority of importations of SARS-CoV-2 in
118 England over Summer 2020 were from coastal European countries. The highest number of
119 cases and onward contacts were from Greece, which was largely exempt from self-isolation
120 requirements (bar some islands in September at the end of the study period). Systematic
121 monitoring of imported SARS-CoV-2 cases would help refine implementation of travel
122 restrictions. Finally, along with multiple studies, this study highlights the use of genomics to
123 monitor and track importations of SARS-CoV-2 mutations of interest; this will be of particular
124 use as the repertoire of clinically relevant SARS-CoV-2 variants expand over time and
125 globally.

126

127

128 **Introduction**

129 A new coronavirus related disease (COVID-19) was first reported in Wuhan, China (2) in
130 December 2019, with the causative virus identified as a novel coronavirus SARS-CoV-2 (3).
131 Since then, SARS-CoV-2 has been imported into virtually every country and region in the
132 world. Understanding and tracking the sources of importations can give important
133 information for policy makers, and for managing the pandemic, by informing policies aimed
134 at reducing the further spread of virus.

135

136 Public health measures can help mitigate and suppress the spread of the virus, but the
137 threat of importations will remain. The available brakes on imported SARS-CoV-2 cases
138 include travel bans, quarantine measures, and testing of returning travellers. These can
139 apply to all countries or targeted to high-risk countries, for variable durations, and with
140 variable degree of enforcement. In England, travel restrictions were assigned on a country
141 by country basis from 6 July 2020 entailing the use of ‘travel-corridors’; travellers returning
142 from countries that were on the travel restrictions list (with ‘closed travel-corridors’) (4) were
143 required to quarantine for 14 days (reduced to 10 days on 15/12/20), or from the 15th
144 December 2020, choose to quarantine for 5 days and then pay for a SARS-CoV-2 diagnostic
145 test (Figure 1). This policy aims to limit onwards transmission of SARS-CoV-2, and as a
146 secondary outcome possibly deter travel to those countries. Upon identification of an
147 imported case, contact tracing and quarantine/self-isolation measures can limit onwards
148 transmission. The CORSAIR study reported that 18.2% of individuals adhered to general
149 SARS-CoV-2 self-isolation guidance recommended by Public Health England in the UK (5).
150 The PHE Isolation Assurance Service however have identified up to 97% self-reported
151 compliance with travel-specific self-isolation guidance (6). These data do not include
152 countries exempt from quarantine, contact-tracing data or link to genomic data to evaluate
153 travel-related clusters.

154

155 Studies from numerous countries have used genome sequencing to complement
156 epidemiological investigations in order to characterise importations of SARS-CoV-2
157 (Supplementary Table 1). Primarily these are in-depth case reports on small datasets but
158 demonstrate the utility of genomics combined with contact tracing. Genomic sequencing of
159 returning travellers was useful in allowing for the first case of reinfection of SARS-CoV-2 in
160 the world to be identified in Hong Kong (7) and identify a new variant of SARS-CoV-2
161 (B.1.177/20A.EU1, variant A222V) (8).

162

163 This study combines contact-tracing data from National Health Service (NHS) Test and
164 Trace (T&T) for probable importation cases with genomic data made available through the

165 COVID-19 Genomics UK (COG-UK) consortium (9), which receives samples from NHS
166 hospital diagnostic labs and mass community testing labs (UK Lighthouse labs network)
167 across the UK. We aimed to characterise the known imported cases and the effectiveness of
168 travel restrictions on onwards transmission.

169

170 A total of 4,207 SARS-CoV-2 positive importation cases were analysed, along with 18,856
171 contacts, of which 888 sequenced genomes were available for comparison to all UK
172 genomic data (131,387 sequences from the UK and in the COG-UK dataset by 5 December
173 2020). The number of contacts reported by a case was used as an indicator of adherence to
174 quarantining.

175 **Methods and materials**

176

177 **Contact tracing and case identification**

178 Contact-tracing data was obtained from T&T. All cases and contacts had a field for
179 demographic data, but this was not always reported (Table 2 and Supplementary Table 3).
180 ‘Highly probable’ travel-related cases were defined as individuals who reported international
181 travel as an activity in the two days before symptom onset/testing. On 12/08/2020 the
182 additional facility to report international travel in the seven days prior to symptom
183 onset/testing became available, and also included in this study and defined as ‘probable’
184 travel-related cases.

185

186 Cases were asked to provide details of all contacts for activities in the 2 days prior to
187 onset/testing up to completing the system which were gathered. If any contacts become
188 cases they would then also be included in T&T data as a case separately, but if they did not
189 report direct travel themselves, then they would not meet the definition for a travel-
190 associated case.

191

192 **Case identification from T&T data**

193 Data included free-text destination city or country. A freetext country and city search with a
194 custom python script on travel-related T&T was used to identify destination country. Results
195 and remaining entries were manually checked and corrected (see Supplementary methods
196 for more details).

197

198 **Clinical samples, Genome sequencing and Quality Control**

199 Clinical samples were collected passively as part of national SARS-CoV-2 testing. This
200 included both community testing through lighthouse labs and testing through hospital

201 diagnostic labs. Samples were sequenced at one of seventeen COG-UK sequencing sites
202 (Figure 1). The samples were prepared for sequencing using either the ARTIC (10) or
203 veSeq (11) protocols, and were sequenced using Illumina or Oxford Nanopore platforms. All
204 samples were uploaded to and processed through COVID-CLIMB pipelines (12,13).
205 Genomes were aligned to the Wuhan Hu-1 reference genome (MN908947.3). Genomes
206 which contained more than 10% missing data were excluded from further analysis to ensure
207 high quality phylogenetic analysis.

208

209 **Lineages and minor variants**

210 Global and UK Lineages (14) were assigned to each genome using Pangolin
211 (<https://github.com/cov-lineages/pangolin>) with analysis performed on COVID-CLIMB (13).
212 Minor variants were pre-defined within the COG-UK database using type_variants
213 (https://github.com/cov-ert/type_variants).

214

215 **Identification of extinct and unique genomes**

216 The 827 high-quality travel-related genomes were compared to the COG-UK dataset on
217 16/10/2020. Genomes were only compared to other genomes with the same UK lineage
218 assigned by COG-UK, since we assume that no relatedness relevant to transmission exists
219 between genomes of different UK lineages. A ‘unique’ genome in the community was
220 deemed to be one that was known to be from a travel-related case and either: (1) A UK
221 lineage that had not been sampled in the previous 4 weeks in the UK, (2) >3 SNPs distance
222 to the closest relative in the COG-UK dataset.

223 Within the same UK lineage we identified those genomes sampled within 4 weeks prior to
224 the genome of interest. We determined the minimum SNP distance between the sequence
225 of interest and these genomes. ‘Unique’ genomes were compared to sequences that were
226 generated in the COG-UK dataset within 2 and 4 weeks after their sampling date, to identify
227 samples with the same UK lineage and within 2 SNPs. These would represent onward
228 transmission or further introductions of similar genomes. The analysis was run with an in-
229 house custom Python script developed by US and RM. Further detail in supplementary
230 methods.

231

232 **Identification of a travel-related SARS-CoV-2 cluster**

233 We used the Polecat clustering tool (<https://cog-uk.github.io/polecat>) to systematically
234 identify outliers in COG-UK genomic dataset and link to contact-tracing data.

235

236 **Statistical analysis**

237 All models were estimated using the glmmTMB package (version 1.0.1) (15) with marginal
238 means and effects calculated using the emmeans package (1.5.2-1) (16) for R (version
239 3.5.1) (17). Figures were generated using R (version 4.0.2) and Microsoft Excel (version
240 1908). The number of contacts per case was modelled using negative binomial regression
241 analysis, to estimate the effect of travel restriction, and whether this varied by age-group,
242 sex of the index case and calendar date. Travel destination and ethnic group were included
243 as covariates (as random effects). A similar approach was taken when estimating the effect
244 of travel restriction on genomic cluster size.

245

246 **Role of the funding source**

247 The funder of the study had no role in study design, data collection, data analysis, data
248 interpretation, or writing of the report.

249 **Results**

250 From 17/03/20 – 04/07/20 the Foreign & Commonwealth Office advised against all non-
251 essential travel worldwide (18). From the 04/07/20 – 01/02/21 travel corridors to countries
252 deemed to be low risk for COVID-19 disease (subject to assessment and change) were
253 established in which returning travellers were no-longer required to quarantine. Persons
254 returning from countries outside this list (except for exemptions e.g. specific employment)
255 were required to quarantine. We sought to both gauge the impact of this policy and to
256 attempt to quantify the numbers of onward transmissions using genomic epidemiology.

257

258 Between 27/05/2020 and 13/09/2020, using contact-tracing data for cases who have tested
259 positive for SARS-CoV-2, we identified 4,207 travel-related cases (Figure 1). Supplementary
260 tables 2 and 3 show the case characteristics.

261

262 Travel to European countries accounted for 85.9% (3612/4207) of cases, of which 51.2%
263 (2155/4207) had visited one of Greece (21.0%, 882/4207), Croatia (16.3%, 685/4207) and
264 Spain (14.0%, 589/4207) (Figure 2 and Table 2). For 284 cases the country of travel was
265 unclear or unknown. Travel restrictions were first eased on 03/07/2020; 2.9% of travel-
266 related cases were recorded before this date. For the countries associated with the highest
267 numbers of imports, the duration of the peak of imported cases differs, with variable
268 association with changes in travel restriction policy (Figure 3). Geographically variations in
269 imported cases across England were apparent, with the greatest number in Greater London
270 (28.6%, 1205/4207) (Figure 2, Supplementary Figures 1 and 2, and Supplementary Table
271 3).

272 The median number of reported contacts per travel-associated case was 3 (IQR 1-5), with a
273 maximum of 172. Overall, travel restriction reduced the number of contacts per case by 40%
274 (rate ratio (R.R.)=0.60, 95% C.I.=0.37-0.95). The mean number of contacts (adjusting and
275 averaging over all over covariates) was 5.85 when no travel restriction was in place and 3.50
276 when there was. The effect of travel restriction varied significantly with age-group and over
277 time (Supplementary Table 4 and Figure 4). The number of contacts per case was greatest
278 for the 16-20 age-group without travel restriction with a marginal mean of 9.0 (95% C.I.=5.6-
279 14.5) but with restriction reduced to 4.7 (95% C.I.=3.9-5.7), and similar to other age-groups.
280 After adjusting for all other covariates the numbers of contacts per imported case was
281 roughly half in September compared to May, June and July, whether or not a travel
282 restriction was in place.

283

284 Transmission patterns identified by analysis of traveller SARS-CoV-2 genomes

285 We next sought to quantify onward transmission from an imported case using genomics.
286 High-quality sequencing data was available for 827/4207 (19.7%) of cases (Figure 1) and
287 demographics of the sequenced cases was broadly similar to the entire travel-related cohort
288 (Supplementary Table 3).

289

290 186/827 (22.4%) imported cases had viral lineages that were sufficiently unique in the COG-
291 UK dataset to monitor onward spread. Of these, 146/186 isolates had not been sampled in
292 the entire UK dataset in the 4 weeks prior and 40/186 isolates were >3 SNPs to their closest
293 matching sequence in the UK dataset.

294

295 To compare the effect of travel restrictions on the subsequent spread of likely imported
296 cases (excluding 18/186 cases before 14/07/2020 to ensure the dates of cases with and
297 without a travel restriction overlapped), the entire COG-UK dataset was interrogated to
298 identify isolates within 2 SNPs of these distinct imported cases during the period 0-2 and 0-4
299 weeks following the importation case. The number of subsequent cases detected during the
300 four weeks since the unique index case increased from a mean of 1.2 new cases where a
301 travel restriction was in place to 11.3 cases where there was not. The proportions of cases
302 leading to a subsequent newly detected case (e.g. likely transmission), and the number of
303 new cases where at least one is detected are shown in Figure 5. Overall, 56/168 of
304 genomes from cases that were genetically unique were detected in subsequent cases (up to
305 four weeks later). Among cases diagnosed after returning from a country where a travel
306 restriction was in place, 25% of (20/81) were detected in later cases (up to four weeks later),
307 rising to 41% (29/71) when cases were imported from a country without a travel restriction.
308 Destination country for 16 index cases was unknown. There was a high variation in the

309 number of subsequent cases matching each genome (range 1 to 210, IQR 0-4) with a small
310 number of imported cases corresponding to large numbers of subsequent cases (Figure 5).

311

312 There was some evidence that imported cases with higher numbers of contacts gave rise to
313 more cases in the subsequent month (Figure 5). Although the number of cases with any
314 subsequent matching genome was not affected by the number of contacts, the average
315 number of subsequent cases detected was substantially higher when the index case had
316 five or more contacts (mean=10.8) compared to none (mean=2.8) or 1 to 4 contacts
317 (mean=1.7).

318

319 To estimate the effect of travel restriction on spread, considering possible confounding
320 effects of calendar date and the mediating effect of reported contacts of the index case, and
321 to test the statistical significance of observed effects, a series of negative binomial
322 regression models were fitted (Figure 5 and Supplementary Table 5). In the four weeks
323 following the index case, fewer genetically-linked cases were reported when the index case
324 was imported from a country with travel restrictions compared to cases from a non-travel
325 restriction country ($R.R.=0.17$, 95% CI=0.05-0.52). When the number of contacts of the
326 index case was included in the model, this rate ratio was attenuated slightly toward 1
327 ($R.R.=0.25$; 0.08-0.81) suggesting a limited mediating effect of the number of contacts of the
328 index case. The effect of contacts was still seen, but the rate of subsequent cases (over four
329 weeks) with the same genome was 4.0 (1.1-15.1) times higher for index cases with five or
330 more reported contacts compared to those with none.

331

332 Genomic identification of a large imported cluster

333 The Polecat Clustering tool (<https://cog-uk.github.io/polecat>) was used to analyse genomes
334 in UK data on 14 September 2020. An outlier cluster was observed (Supplementary Figure
335 3). This cluster (UK1897) was associated with high diversity with a long stem length
336 compared to samples from the UK, suggesting that this lineage evolved outside the UK. The
337 geographic distribution of this lineage is demonstrated in Supplementary Figure 4, likely
338 representing multiple importations across the UK (Supplementary Figure 4). This cluster
339 contained the D614G mutation but no others associated with increased transmission. The
340 root of the cluster was associated with a Swiss phylotype when linked to data in GISAID.
341 During the course of the study period (04/08/2020 to 14/09/2020) there were 304 genomes.
342 These were linked to 238 individuals, of whom 159 could be linked to a contact-tracing
343 record. 143/159 had contact-tracing information indicating international travel or not. 72/143
344 (50.3%) individuals were linked to international travel and associated with ten,

345 dispersed European countries (four individuals had travel to more than one European
346 Country) and most commonly Croatia (35/72, 48.6%) (Supplementary Figure 5). A further 4
347 cases were identified as contacts of individuals who had reported travel to mainland Europe.
348 There is a trend towards an increased proportion of cases that do not report travel over time,
349 and possibly representing dispersion and onwards transmission locally of this lineage
350 (Supplementary Figure 6).

351

352 Lineage diversity of imported SARS-CoV-2 cases

353
354 The 827 imported genomes reflected 238 UK lineages (see Supplementary Materials), of
355 which 214 were seen less than 5 times (142 singletons) and 24 were seen 5 or more times
356 (Supplementary Table 6). The most commonly observed were UK5 (152 genomes, 18.4%)
357 and UK1897 (73 genomes, 8.8%). There were 39 global lineages within the genomes. The
358 most commonly observed lineages were B.1.1 (159 genomes, 19.2%) and B.1.177 (128
359 genomes, 15.5%) (Supplementary Tables 7 and 8). Further, potentially functionally important
360 mutations were identified (Supplementary Table 9 and Supplementary Figure 8): D614G,
361 824/827 (99.6%) cases; N439K, 65/827 (7.86%) of cases; A222V, 131/827 (15.84%) of
362 cases. ΔH69/V70 was identified in 53 cases associated with lineage B.1.258. We
363 evaluated the introduction of A222V (B.1.177) over time, demonstrating a clear
364 epidemiological link to Spain through contact tracing (Supplementary Figure 9). By the end
365 of the study period, this variant was introduced from 16 separate countries indicating
366 dispersion across Europe (Supplementary Figures 10). The mutations co-occur, with the
367 proportion of cases represented by these combinations varying over time (Supplementary
368 Figure 11).

369

370 Discussion

371 We demonstrate, through the analysis of both contact-tracing data and the use of genomics,
372 that travel restrictions (use of travel corridors) reduced the detected linked cases of SARS-
373 COV-2. From 27/05/2020 to 13/09/2020, 85.9% of importations were from European
374 countries with three countries accounting for 51.2% of all imported cases. Along with travel
375 restriction, age was a significant determinant of onwards contacts, and this effect was
376 mitigated with closing travel corridors. After a period of national lockdown, systematic
377 monitoring of imported genomes can identify sequences that are sufficiently unique and
378 provide utility for monitoring of onwards transmission.

379

380 Whilst the study period covers nearly 5 months, the importations are concentrated after the
381 implementation of travel corridors. The peaks for imports for each country occur at different

382 times and with different epidemic curves. For the most common destination, barring Spain,
383 imported cases appear to reduce after country-specific travel restrictions. Importations from
384 Greece came at the end of August and continued into September, with the steepest of all
385 curves. No travel restrictions were imposed on Greece during this time period and it was the
386 source of greatest imported SARS-CoV-2 cases during this study period. This highlights the
387 need for active surveillance of imported cases of SARS-CoV-2 for the introduction of travel
388 corridors in a timely manner. London accounts for 15.4% of the population in England (19),
389 but had 28.6% of the imports, possibly reflecting a younger age demographic. The overall
390 R₀ remained largely similar to other parts of the country during the study period potentially
391 indicating imports are unlikely to have had a substantial impact on onward infection rates
392 (20). Other explanations may include a small possible effect of higher seropositivity rates in
393 London (17.5%, 27/4/2020, (21)) from the first wave of SARS-CoV-2 infections in England
394 seen and a potential lower detection rate in London.

395

396 The number of onwards contacts are significantly reduced by the introduction of travel
397 restrictions. Age is also a significant determinant of onwards contacts, with the 16-20 year
398 old age-group representing the greatest number of travel-related cases and onwards
399 contacts. This identifies an opportunity to direct public health awareness campaigns to
400 younger travellers, with the intention to promote behaviours that will reduce the risk of
401 SARS-CoV-2 acquisition and enhance compliance with quarantine on return to the UK.

402

403 The use of genomic sequencing, specifically after a period of national lockdown, allowed
404 identification of a cohort of unique genomes that could be monitored for cluster growth. The
405 cluster size for genomes that were related to a country without travel restrictions was
406 significantly higher than those related to countries under travel restriction guidance. Further,
407 when comparing the number of genomes in a cluster to the number of contacts that their
408 respective cases reported, there was a trend towards a positive correlation suggesting self-
409 isolation is effective. The total effect of travel restrictions was not explained by forward
410 contacts alone and it is a possible that a reduction in the absolute number of individuals
411 travelling to countries with travel restrictions also contributes to this.

412

413 The Polecat Clustering Tool highlighted a cluster that developed largely through travel to
414 Croatia. Programmatic analysis of genomics data can therefore identify putative importation
415 clusters. Integration with contact-tracing information was vital for the true picture of the
416 sources of introduction and the subsequent spread, due to the SARS-CoV-2 sequencing
417 bias observed globally. In this instance an introduced lineage was associated with wide-
418 spread dispersal and onward transmission during a period when England had limited social

419 distancing measures. The lineage, B.1.160, associated with this cluster is not associated
420 with increased transmissibility but this study highlights a supplementary method for the
421 detection and monitoring of expanding imported clusters and could prove particularly useful
422 for the investigation of introduced variants of concern.

423

424 Our study is subject to multiple limitations. The COG-UK dataset has a limited sequencing
425 coverage across England and cluster sizes detected will under-estimate absolute numbers
426 (Supplementary Figure 12). The dates of country-specific travel restriction guidance was
427 aligned with the date of travel-related case sampling, the earliest date reliably available. The
428 effect of this should not however markedly affect results or conclusions; the period of travel
429 restrictions are long and the effect size seen is large and therefore this discrepancy is
430 unlikely to account for the significant difference observed. Further, most countries
431 accounting for the imported SARS-CoV-2 cases went into a period of a travel restriction over
432 the study period; by using a date later than the date of return from travel, we are more likely
433 to over-represent contacts for countries under ‘travel-restriction’ guidance. Our study
434 evaluates a period of time following a national lockdown and the associated reduced travel
435 would likely exaggerate the diversity of genomes when compared with the COG-UK dataset.
436 Outcomes such as travel and the number of contacts are self-reported by cases which will
437 have inherent biases. Finally, there will be an artificial reduction in cases at the end of the
438 study period when accounting for case incubation period, testing and report, with data
439 provided 3 days after study close.

440

441 Conclusions

442 We present an integrated epidemiological and genomic evaluation of the largest dataset of
443 confirmed SARS-CoV-2 imported cases into the UK (or any other country) to our knowledge.
444 We demonstrate the efficacy of closing ‘travel-corridors’ in reducing onward transmission of
445 imported cases, and highlight the importance for targeted public health campaigns to reduce
446 SARS-CoV-2 importations and onwards transmission. Our data demonstrates how routine
447 genomic monitoring of travel-related cases could be used to refine travel restrictions and the
448 genomic diversity of the SARS-CoV-2 import cases.

449

450

451

452

453

454 **Funding**

455 DA is a Clinical PhD Fellow and gratefully supported by the Wellcome Trust [Grant number:
456 222903/Z/21/Z]. EMH is supported by a UK Research and Innovation (UKRI) Fellowship:
457 MR/S00291X/1. AJP, TLV, GMS gratefully acknowledge the support of the Biotechnology
458 and Biological Sciences Research Council (BBSRC); their research was funded by the
459 BBSRC Institute Strategic Programme Microbes in the Food Chain BB/R012504/1 and its
460 constituent project BBS/E/F/000PR10352, also Quadram Institute Bioscience BBSRC
461 funded Core Capability Grant (project number BB/CCG1860/1). The COVID-19 Genomics
462 UK (COG-UK) Consortium is supported by funding from the Medical Research Council
463 (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research
464 (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. The
465 funders had no role in study design, data collection and analysis, decision to publish, or
466 preparation of the manuscript.

467

468 **Author contributions**

469 All authors read the manuscript and consented to its publication.
470 DA led the study.
471 DA, AJP, GS wrote the first draft of the manuscript.
472 All authors contributed to revision of the first draft of the manuscript.
473 DA, US, AJP, RM, NE undertook data analysis.
474 GMS provided statistical guidance and analysis.
475 DA, SP, NG, EG contributed to data curation.
476 GJH, CC, CT, SL, AH provided oversight over data acquisition and data definitions.
477 TLV wrote scripts to perform analysis.
478 NMT undertook the literature search.
479 DA, US, RM, EV, MC, EMH contributed to study design
480 MC, EMH, SJP conceived the study and provided overall leadership.
481 DA, MC and SJP provided clinical oversight.

482

483 **Conflicts of interests and disclosures**

484 None declared.

485

486 **Ethics**

487 This study was conducted as part of surveillance for COVID-19 infections under the
488 auspices of Section 251 of the NHS Act 2006 and/or Regulation 3 of The Health Service
489 (Control of Patient Information) Regulations 2002. They therefore did not require individual

490 patient consent or ethical approval. Public Health England affiliated authors had access to
491 identifiable patient data. Other authors only had access to anonymised or summarised data.
492 The COG-UK study protocol was approved by the Public Health England Research Ethics
493 Governance Group (reference: R&D NR0195).

494

495 Acknowledgements

496 We thank members of the COVID-19 Genomics Consortium UK and Test and Trace contact
497 tracers or their contributions to generating the data used in this study. We thank Sarah
498 Mitchell from the Department of Plant Sciences, University of Cambridge, for direction on
499 statistical analysis.

500

501 Data availability

502 Assembled/consensus genomes are available from GISAID (22) subject to minimum quality
503 control criteria. Raw reads are available from European Nucleotide Archive (ENA) (23). All
504 genomes, phylogenetic trees, basic metadata are available from the COG-UK consortium
505 website (<https://www.cogconsortium.uk/data>). For confidentiality reasons, extended
506 metadata (24) is not publicly available, however some may be available upon request from
507 Public Health England.

508

509 References

- 510 1. Plessis L du, McCrone JT, Zarebski AE, Hill V, Ruis C, Gutierrez B, et al. Establishment
511 and lineage dynamics of the SARS-CoV-2 epidemic in the UK. *Science*. 2021 Feb
512 12;371(6530):708–12.
- 513 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
514 with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020 Feb
515 15;395(10223):497–506.
- 516 3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients
517 with Pneumonia in China, 2019. *N Engl J Med*. 2020 Feb 20;382(8):727–33.
- 518 4. GOV UK. Coronavirus (COVID-19): travel corridors [Internet]. GOV.UK. 2020 [cited 2020
519 Nov 19]. Available from: <https://www.gov.uk/guidance/coronavirus-covid-19-travel-corridors>
- 521 5. Smith LE, Potts HW, Amlôt R, Fear NT, Michie S, Rubin GJ. Adherence to the test, trace
522 and isolate system: results from a time series of 21 nationally representative surveys in
523 the UK (the COVID-19 Rapid Survey of Adherence to Interventions and Responses
524 [CORSAIR] study). *medRxiv*. 2020 Sep 18;2020.09.15.20191957.
- 525 6. Border Force. Data on health measures at the UK border [Internet]. GOV.UK. 2020 [cited
526 2021 Feb 19]. Available from: <https://www.gov.uk/government/publications/data-on-health-measures-at-the-uk-border/data-on-health-measures-at-the-uk-border>

- 528 7. To KK-W, Hung IF-N, Ip JD, Chu AW-H, Chan W-M, Tam AR, et al. COVID-19 re-
529 infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole
530 genome sequencing. *Clin Infect Dis* [Internet]. 2020 Aug 25 [cited 2020 Sep 8];
531 Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1275/5897019>
- 533 8. Hodcroft EB, Zuber M, Nadeau S, Comas I, Candelas FG, Consortium S-S, et al.
534 Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of
535 2020. *medRxiv*. 2020 Oct 28;2020.10.25.20219063.
- 536 9. COG-UK. An integrated national scale SARS-CoV-2 genomic surveillance network.
537 *Lancet Microbe* [Internet]. 2020 Jun 2 [cited 2020 Jun 9];0(0). Available from:
538 [https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247\(20\)30054-9/abstract](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30054-9/abstract)
- 539 10. Quick J. nCoV-2019 sequencing protocol v2. 2020 Apr 9 [cited 2020 Apr 25]; Available
540 from: <https://www.protocols.io/view/ncov-2019-sequencing-protocol-v2-bdp7i5rn>
- 541 11. Bonsall D, Golubchik T, Cesare M de, Limbada M, Kosloff B, MacIntyre-Cockett G, et
542 al. A Comprehensive Genomics Solution for HIV Surveillance and Clinical Monitoring in
543 Low-Income Settings. *J Clin Microbiol* [Internet]. 2020 Sep 22 [cited 2021 Mar
544 10];58(10). Available from: <https://jcm.asm.org/content/58/10/e00382-20>
- 545 12. Nicholls SM, Poplawski R, Bull MJ, Underwood A, Chapman M, Abu-Dahab K, et al.
546 MAJORA: Continuous integration supporting decentralised sequencing for SARS-CoV-
547 2 genomic surveillance. *bioRxiv*. 2020 Oct 7;2020.10.06.328328.
- 548 13. Connor TR, Loman NJ, Thompson S, Smith A, Southgate J, Poplawski R, et al. CLIMB
549 (the Cloud Infrastructure for Microbial Bioinformatics): an online resource for the
550 medical microbiology community. *Microb Genomics*. 2016;2(9):e000086.
- 551 14. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic
552 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat
553 Microbiol*. 2020 Nov;5(11):1403–7.
- 554 15. Brooks ME, Kristensen K, Van Bentem KJ, Magnusson A, Berg CW, Nielsen A, et al.
555 glmmTMB balances speed and flexibility among packages for zero-inflated generalized
556 linear mixed modeling. *R J*. 2017;9(2):378–400.
- 557 16. Lenth R, Singmann H, Love J, Buerkner P, Herve M. Emmeans: Estimated marginal
558 means, aka least-squares means. *R Package Version*. 2018;1(1):3.
- 559 17. Team RC. R: a language and environment for statistical computing. *R Foundation for
560 Statistical Computing*, Vienna. *WwwR-Proj*. 2018;
- 561 18. Foreign & Commonwealth Office. Travel advice: coronavirus (COVID-19) [Internet].
562 GOV.UK. 2021 [cited 2021 Feb 19]. Available from:
563 <https://www.gov.uk/guidance/travel-advice-novel-coronavirus>
- 564 19. Office for National Statistics, National Records of Scotland, Northern Ireland Statistics
565 and Research Agency. 2011 Census aggregate data (Data downloaded: 1 June 2016)
566 [Internet]. UK Data Service; 2016. Available from:
567 <https://beta.ukdataservice.ac.uk/datacatalogue/studies/study?id=7427>
- 568 20. DHSC, SAGE. The R value and growth rate in the UK [Internet]. GOV.UK. 2021 [cited
569 2021 Feb 19]. Available from: <https://www.gov.uk/guidance/the-r-number-in-the-uk>

- 570 21. GOV UK. Sero-surveillance of COVID-19 [Internet]. GOV.UK. 2020 [cited 2020 Nov
571 19]. Available from: <https://www.gov.uk/government/publications/national-covid-19->
572 surveillance-reports/sero-surveillance-of-covid-19
- 573 22. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision
574 to reality. *Eurosurveillance*. 2017 Mar 30;22(13):30494.
- 575 23. Cochrane G, Karsch-Mizrachi I, Takagi T, Sequence Database Collaboration IN. The
576 International Nucleotide Sequence Database Collaboration. *Nucleic Acids Res*. 2016
577 Jan 4;44(D1):D48–50.
- 578 24. Griffiths EJ, Timme RE, Page AJ, Alikhan N-F, Fornika D, Maguire F, et al. The
579 PHA4GE SARS-CoV-2 Contextual Data Specification for Open Genomic Epidemiology.
580 2020 Aug 9 [cited 2020 Sep 3]; Available from:
581 <https://www.preprints.org/manuscript/202008.0220/v1>
- 582 25. Au CH, Chan WS, Lam HY, Ho DN, Lam SYM, Zee JST, et al. Genome Sequences of
583 SARS-CoV-2 Strains Detected in Hong Kong. *Microbiol Resour Announc*. 2020
584 Jul;9(31):e00697-20.
- 585 26. Böhmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al.
586 Investigation of a COVID-19 outbreak in Germany resulting from a single travel-
587 associated primary case: a case series. *Lancet Infect Dis*. 2020;20(8):920–8.
- 588 27. Cohen-Gihon I, Israeli O, Shifman O, Stein D, Achdout H, Weiss S, et al. Coding-
589 Complete Genome Sequences of Two SARS-CoV-2 Isolates from Early Manifestations
590 of COVID-19 in Israel. *Microbiol Resour Announc*. 2020 Jul;9(28):e00677-20.
- 591 28. Jesus JG de, Sacchi C, Candido D da S, Claro IM, Sales FCS, Manuli ER, et al.
592 Importation and early local transmission of COVID-19 in Brazil, 2020. *Rev Inst Med
593 Trop Sao Paulo*. 2020;62:e30.
- 594 29. do Nascimento VA, Guerra Corado A de L, do Nascimento FO, Araujo da Costa AK,
595 Gomes Duarte DC, Bessa Luz SL, et al. Genomic and phylogenetic characterisation of
596 an imported case of SARS-CoV-2 in Amazonas State, Brazil. *Mem Inst Oswaldo Cruz*.
597 2020;115:e200310.
- 598 30. Du P, Ding N, Li J, Zhang F, Wang Q, Chen Z, et al. Genomic surveillance of COVID-
599 19 cases in Beijing. *Nat Commun*. 2020 30;11(1):5503.
- 600 31. Garcés-Ayala F, Araiza-Rodríguez A, Mendieta-Condado E, Rodríguez-Maldonado AP,
601 Wong-Arámbula C, Landa-Flores M, et al. Full genome sequence of the first SARS-
602 CoV-2 detected in Mexico. *Arch Virol*. 2020 Sep;165(9):2095–8.
- 603 32. Giandhari J, Pillay S, Wilkinson E, Tegally H, Sinayskiy I, Schuld M, et al. Early
604 transmission of SARS-CoV-2 in South Africa: An epidemiological and phylogenetic
605 report. *Int J Infect Dis*. 2021 Feb 1;103:234–41.
- 606 33. Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019-nCoV
607 in Italy: Where they come from? *J Med Virol*. 2020;92(5):518–21.
- 608 34. Gómez-Carballa A, Bello X, Pardo-Seco J, Pérez Del Molino ML, Martinón-Torres F,
609 Salas A. Phylogeography of SARS-CoV-2 pandemic in Spain: a story of multiple
610 introductions, micro-geographic stratification, founder effects, and super-spreaders.
611 *Zool Res*. 2020 Nov 18;41(6):605–20.

- 612 35. Gong Y-N, Tsao K-C, Hsiao M-J, Huang C-G, Huang P-N, Huang P-W, et al. SARS-
613 CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade
614 possibly associated with infections in Middle East. *Emerg Microbes Infect.* 2020 Jan
615 1;9(1):1457–66.
- 616 36. Jia Y, Yang C, Zhang M, Yang X, Li J, Liu J, et al. Characterization of eight novel full-
617 length genomes of SARS-CoV-2 among imported COVID-19 cases from abroad in
618 Yunnan, China. *J Infect.* 2020;81(2):e96–8.
- 619 37. Kouriba B, Dürr A, Rehn A, Sangaré AK, Traoré BY, Bestehorn-Willmann MS, et al.
620 First Phylogenetic Analysis of Malian SARS-CoV-2 Sequences Provides Molecular
621 Insights into the Genomic Diversity of the Sahel Region. *Viruses.* 2020
622 Nov;12(11):1251.
- 623 38. Kumar P, Pandey R, Sharma P, Dhar MS, A V, Uppili B, et al. Integrated genomic view
624 of SARS-CoV-2 in India. *Wellcome Open Res.* 2020;5:184.
- 625 39. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic
626 traveler, China. *Emerg Infect Dis.* 2020;26(9):2260–3.
- 627 40. Lu J, du Plessis L, Liu Z, Hill V, Kang M, Lin H, et al. Genomic Epidemiology of SARS-
628 CoV-2 in Guangdong Province, China. *Cell.* 2020 May 28;181(5):997–+.
- 629 41. Manning JE, Bohl JA, Lay S, Chea S, Sovann L, Sengdoeurn Y, et al. Rapid
630 metagenomic characterization of a case of imported COVID-19 in Cambodia. *BioRxiv*
631 Prepr Serv Biol. 2020 Mar 5;
- 632 42. Marquez S, Prado-Vivar B, Guadalupe JJ, Gutierrez Granja B, Jibaja M, Tobar M, et al.
633 Genome sequencing of the first SARS-CoV-2 reported from patients with COVID-19 in
634 Ecuador. *MedRxiv Prepr Serv Health Sci.* 2020 Jun 14;
- 635 43. Puenpa J, Suwannakarn K, Chansaenroj J, Nilyanimit P, Yorsaeng R, Auphimai C, et
636 al. Molecular epidemiology of the first wave of severe acute respiratory syndrome
637 coronavirus 2 infection in Thailand in 2020. *Sci Rep.* 2020 Oct 6;10(1):16602.
- 638 44. Rockett RJ, Arnott A, Lam C, Sadsad R, Timms V, Gray K-A, et al. Revealing COVID-
639 19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based
640 modeling. *Nat Med.* 2020;26(9):1398–404.
- 641 45. Seemann T, Lane CR, Sherry NL, Duchene S, da Silva AG, Caly L, et al. Tracking the
642 COVID-19 pandemic in Australia using genomics. *Nat Commun.* 2020 Sep
643 1;11(1):4376.
- 644 46. Sekizuka T, Kuramoto S, Nariai E, Taira M, Hachisu Y, Tokaji A, et al. SARS-CoV-2
645 Genome Analysis of Japanese Travelers in Nile River Cruise. *Front Microbiol.* 2020 Jun
646 5;11:1316.
- 647 47. Stange M, Mari A, Roloff T, Seth-Smith HM, Schweitzer M, Brunner M, et al. SARS-
648 CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked
649 to mass gathering events. *medRxiv.* 2020 Nov 4;2020.09.01.20186155.

650
651
652
653

654 Tables

655

Country	Cases		Sequenced samples from cases (passed QC)		Percentage of cases sequenced by country of travel
	N	%	N	%	
Greece	882	21.0%	166	20.1%	18.8%
Croatia	685	16.3%	162	19.6%	23.6%
Spain	589	14.0%	106	12.8%	18.0%
Unknown	282	6.7%	57	6.9%	20.2%
France	223	5.3%	52	6.3%	23.3%
Turkey	187	4.4%	21	2.5%	11.2%
Portugal	111	2.6%	20	2.4%	15.2%
Malta	99	2.4%	15	1.8%	22.6%
Italy	93	2.2%	21	2.5%	16.5%
Poland	85	2.0%	14	1.7%	15.4%
Romania	78	1.9%	13	1.6%	16.7%
Czech Republic	65	1.5%	10	1.2%	27.9%
Albania	61	1.4%	12	1.5%	24.6%
Hungary	61	1.4%	17	2.1%	21.8%
India	57	1.4%	14	1.7%	13.2%
Pakistan	55	1.3%	12	1.5%	20.7%
Netherlands	38	0.9%	5	0.6%	25.0%
Germany	29	0.7%	6	0.7%	12.5%
Switzerland	28	0.7%	7	0.8%	18.8%
Kosovo	24	0.6%	3	0.4%	19.7%
Total cases	4207		827		19.7%

656

657

Table 1: The top 20 countries reported as the travel destination for importations of SARS-CoV-2 into England and the associated number of samples sequenced from travel-related cases

658

659

660

661

Demographic	Cases	Total contacts of cases	contacts reported per case
Sex			
Male	2193	9835	4.5
Female	1933	8578	4.4
Unknown	82	224	3.1
Age			
0-5	51	183	3.6


6-10	45	124	2.8
11-15	75	321	4.3
16-20	1086	7473	6.9
21-25	843	3536	4.2
26-30	685	2091	3.1
31-35	413	1312	3.2
36-40	278	939	3.4
41-45	185	566	3.1
46-50	169	723	4.3
51-55	130	469	3.6
56-60	121	434	3.6
61-65	57	229	4.0
66-70	30	116	3.9
71-75	20	63	3.2
76-80	7	16	2.3
81-85	7	39	5.6
86-90	3	3	1.0
91-95	0	0	NA
Unknown	2		
Ethnic group			
White			
English/Welsh/Scottish/Northern Irish/British	2509	12745	5.1
Irish	35	121	3.5
Gypsy or Irish Traveller	0	0	NA
Any other White background	583	1755	3.0
Mixed/Multiple ethnic groups			
White and Black Caribbean	42	284	6.8
White and Black African	25	108	4.3
White and Asian	49	216	4.4
Any other Mixed/Multiple ethnic background	44	147	3.3
Asian/Asian British			
Indian	103	481	4.7
Pakistani	79	306	3.9
Bangladeshi	27	82	3.0
Chinese	6	2	0.3
Any other Asian background	62	199	3.2
Black/ African/Caribbean/Black British			
African	58	152	2.6
Caribbean	12	36	3.0

Any other Black/African/Caribbean background	12	28	2.3
Other ethnic group			
Arab	0	0	NA
Any other ethnic group	110	367	3.3
Other			
Prefer not to say	65	135	2.1
Unknown	386	1473	3.8
Region			
London	1205	4275	3.5
South East	622	3211	5.2
North West	584	2323	4.0
East of England	395	2079	5.3
South West	328	1960	6.0
Yorkshire and Humber	327	1411	4.3
West Midlands	299	1259	4.2
East Midlands	251	1351	5.4
North East	161	660	4.1
Not stated	35	108	3.1
Country			
Greece	882	5587	6.3
Croatia	685	3913	5.7
Spain	589	1521	2.6
Unknown	282	988	3.5
France	223	815	3.7
Turkey	187	702	3.8
Portugal	111	439	4.0
Malta	99	492	5.0
Italy	93	390	4.2
Poland	85	417	4.9
Romania	78	189	2.4
Hungary	67	137	2.0
Czech Republic	66	239	3.6
Albania	61	140	2.3
India	57	223	3.9
Pakistan	55	269	4.9
Netherlands	38	166	4.4
Germany	29	101	3.5

Switzerland	28	123	4.4
Kosovo	24	64	2.7

662 **Table 2: Contacts per case related to Sex, Age, Ethnic Group, Region of residence
663 and reported Travel Destination**

664 **Figures**



665
666 **Figure 1a: Flow diagram of travel-related case ascertainment from Test and Trace
667 data and subsequent genome availability.** Cases were defined as 'highly probable' and
668 'probable'. 'Highly probable' travel-related cases were defined as individuals who reported
669 international travel as an activity in the two days before symptom onset/testing. On
670 12/08/2020 the additional facility to report international travel in the seven days prior to
671 symptom onset/testing became available, and also included in this study and defined as
672 'probable' travel-related cases.
673




Figure 1b: Flow diagram relaying contacts ascertained of cases from Test and Trace data





Figure 1c: Timeline of study period (27/05/2020 to 13/09/2020) and associated policy changes on travel introduced in England. Travel restrictions were assigned on a country by country basis from 6 July 2020. Travellers returning from countries that were on the travel restrictions list (4) were required to self-isolate for 14 days (*reduced to 10 days on 15/12/20), or from the 15th December 2020, choose to self-isolate for 5 days and then pay for a SARS-CoV-2 diagnostic test (test and release)




698
699 **Figure 2a: Countries where importations originated. Countries with less than 5**
700 **importations were excluded for confidentiality reasons.**



701
702 **Figure 2b: Destinations of imported cases within England. Areas with less than 3**
703 **cases have been excluded**

704


705



706
707
708
709
710
711
712

Figure 3: Frequency of importations over time for the top 4 most common countries of travel reported by individuals testing positive for SARS-CoV-2 during the study period. SARS-CoV-2 case numbers in returning travellers by the four most popular countries of travel reported by cases representing 2379/4207 (56.5%) of known travel-related cases. The shaded areas represent the period of time when the countries did not have restrictive travel guidance in place.

713



714
715
716
717
718
719
720
721
722
723
724
725

Figure 4: The effect of travel restriction on contacts per imported case of SARS-CoV-2. 2. Estimated marginal mean number of contacts per imported case (a) overall, (b) by age-group and (c) by date of test comparing countries with travel restriction guidance (closed 'travel-corridors') in place and those without (open 'travel-corridors'). All estimates are provided with 95% confidence intervals.




Figure 5: The effect of travel restrictions on the subsequent spread of likely imported cases as determined by genomics. Panel A: The proportion of imported cases with any matching genome detected over the two or four weeks following index test result. Panel B: The number of genomes matching the index case, with zeros excluded. Panel A and B compare countries with travel restriction guidance (closed ‘travel-corridors’) in place and those without (open ‘travel-corridors’). Panel C: The proportion of imported cases with any matching genome detected over the two or four weeks following index test result. Panel D:

781 The number of genomes matching the index case, with zeros excluded. Panel E: Estimated
782 marginal mean number of genomes detected after 2 weeks or 4 weeks matching an index
783 genome, stratified by travel restriction and stratified by number of contacts. In all panels,
784 boxes correspond to median and interquartile range, and error bars correspond to 95%
785 confidence intervals.

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833